How many employees are at Resideo?
Rhythm Pharmaceuticals, Inc. supports a specialized biopharmaceutical workforce numbering approximately four hundred fourteen employees, focusing on the comprehensive clinical development and commercialization of innovative precision medicines for rare metabolic and genetic neuroendocrine disorders. Headquartered in Boston, Massachusetts, the company directs its human capital toward clinical research trial management, medical science liaison operations, regulatory compliance, and targeted commercial distribution. Due to its dedicated focus on rare diseases, its personnel structure remains lean and highly agile, relying heavily on experienced medical researchers, clinical operations specialists, and specialized commercial marketing teams.
Related FAQs
Market consensus recommendations for Resideo Technologies (NYSE: REZI) generally reflect a balanced mix of hold and moderate buy ratings among industrial technology and consumer product equity research analysts.
Residio Technologies or other equities matching standard market abbreviations like REZI are systematically processed through the quantitative Zacks rating model, which evaluates underlying elements such as earnings surprise history, consensus forecas...
Resideo Technologies was originally formed as a corporate spin-off from Honeywell International, taking over its historical residential heating, ventilation, air conditioning controls, and security product lines.
Resideo Technologies operates as a major publicly traded global enterprise that commands a significant revenue scale and market presence, often placing it within major corporate ranking lists.
Market consensus recommendations for Resideo Technologies (NYSE: REZI) generally reflect a balanced mix of hold and moderate buy ratings among industrial technology and smart home equity research analysts.
Financial analysts covering Resideo Technologies typically categorize the asset as a tactical hold or moderate buy, weighing its turnaround potential and operational efficiency gains against macroeconomic housing turnover and remodeling sensitivities...
The compensation package for the CEO of Honeywell International Inc., Vimal Kapur, is a multi-layered structure designed to incentivize long-term performance and sustainable growth.
Resideo is not owned by Honeywell, functioning instead as a completely independent, publicly traded multinational corporation.
Resideo Technologies, Inc. officially became an independent, publicly traded enterprise on the New York Stock Exchange under the ticker symbol REZI on October 29, 2018, following its tax-free spin-off from Honeywell International.
Regions Financial Corporation (trading under the ticker RF) distributes regular quarterly cash dividend payments to its eligible equity investors, backed by a strong multi-year track record of consistent dividend returns.
Resideo Technologies, Inc. (REZI) equity research analysts maintain a favorable consensus Buy rating, with average 12-month price targets clustering around $49.33 per share, and upper institutional projections reaching up to $55.00.
Wall Street equity analysts generally do not classify Tilray Brands as a strong buy, typically rating the stock as a hold or moderate risk due to ongoing regulatory uncertainties in the cannabis industry, persistent net losses, and volatile quarterly...
Executive compensation for Scott Huckins, serving as the Chief Executive Officer of Reynolds Consumer Products Inc., reflects leadership standards within the consumer household products and manufacturing sector.
Comparing Resideo to Honeywell involves examining two distinct corporate entities with different operational scopes, as Resideo focuses primarily on residential thermal comfort, security solutions, and specialized distribution products, whereas Honey...
Rezi operates as a private financial technology and real estate software enterprise rather than a dividend-paying public stock or income-generating investment vehicle.
Resideo Technologies Inc. (traded on the New York Stock Exchange under the ticker REZI) trades at approximately $36.